Human Umbilical Cord Mesenchymal Stem Cells-Derived Exosomes Can Alleviate the Proctitis Model Through Tlr4/Nf-Κb Pathway Publisher



Soltani ZE^{1, 2} ; Elahi M^{1, 3} ; Golroudbari HT^{1, 4} ; Badripour A⁴ ; Nazari H⁵ ; Heiranitabasi A¹ ; Asbagh RA^{1, 4} ; Ohadi MAD^{1, 4} ; Shabani M¹ ; Mahboudi M¹ ; Sarzaeim M^{4, 5} ; Mahdavi SA³ ; Behboudi B² ; Keramati MR² Show All Authors
Source: Journal of Cellular and Molecular Anesthesia Published:2023

Abstract

Background: Proctitis is a significant concern of inflammatory bowel diseases, especially ulcerative colitis. Exosomes are a new method for treating many diseases by their immunosuppressive and tissue-repairing potential. Here, we tried Mesenchymal stem cells (MSCs)-derived Exosomes for treating the proctitis model of rats. Materials and Methods: Rats were assigned into four groups: sham, control group, rectal, and intraperitoneal exosome injection. The proctitis model was induced by rectal administration of 4% acetic acid. The exosome was derived from human MSCs isolated from human umbilical cords. After seven days, rectum samples were assessed for histopathological, IHC, and PCR analysis. Results: The histopathologic scores, collagen deposition, and the expression of NF-κB, TLR4, TNFα, IL-6, and TGFβ were decreased in intraperitoneal exosome compared to controls. The result was not promising for the rectal administration of exosomes. Conclusion: Exosomes can suppress the inflammatory response in the proctitis model and improve the rectum's healing process. Exosomes can inhabit the NF-κB/TLR4 pathway and downstream pro-inflammatory cytokines. This study implicates the therapeutic benefits of exomes in treating proctitis. © 2023 Shahid Beheshti University of Medical Sciences, Anesthesiology Research Center. All rights reserved.